Abstract
Fentanyl is a key therapeutic used in anaesthesia and pain management. It is also increasingly used illicitly and is responsible for a large and growing number of opioid overdose deaths, especially in North America. A number of factors have been suggested to contribute to fentanyl's lethality, including rapid onset of action, in vivo potency, ligand bias, induction of muscle rigidity and reduced sensitivity to reversal by naloxone. Some of these factors can be considered to represent "anomalous" pharmacological properties of fentanyl when compared to prototypical opioid agonists such as morphine. In this review, we examine the nature of fentanyl's "anomalous" properties, to determine whether there really is a pharmacological basis to support the existence of such properties, and also discuss whether such properties are likely to contribute to overdose deaths involving fentanyls.
Original language | English |
---|---|
Journal | British Journal of Pharmacology |
Early online date | 2 Jul 2021 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Funding Information:This study was supported by UKRI Medical Research Council (MRC) grant (MR/S010890/1) as well as UKRI Biotechnology and Biological Sciences Research Council (BBSRC) studentships awarded to K.S. and N.R.‐G. under the South West Biosciences (SWBio) DTP scheme (Grant BB/J014400/1).
Publisher Copyright:
© 2021 The British Pharmacological Society